Roche disclosed phase 3 results showing its BTK inhibitor fenebrutinib was non‑inferior to Ocrevus (ocrelizumab) in primary progressive multiple sclerosis (PPMS), reducing the risk of confirmed disability progression by 12%, Roche said at ACTRIMS26. The company released detailed trial numbers to explain the statistical win and its clinical readouts. Roche linked the outcome to its BTK program’s potential to address neuroinflammation in PPMS, presenting the data at ACTRIMS26 to target neurologists and investors. The company provided efficacy and safety breakdowns to contextualize the modest but statistically significant advantage. BTK inhibitors target Bruton’s tyrosine kinase, a signaling node implicated in B‑cell and myeloid cell activity; the class is being evaluated across multiple autoimmune and neuroinflammatory indications.